Promising combo tackles Hard-to-Treat breast cancer

NCT ID NCT07647016

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of two drugs—deruxtecan (a targeted chemotherapy) and ivonescimab (an immunotherapy)—in people with hormone receptor-positive, HER2-negative advanced breast cancer. The study aims to see how well the combination shrinks tumors and how safe it is. About 53 participants will be enrolled at Fudan University in Shanghai.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Trastuzumab Deruxtecan (a targeted chemotherapy) and Ivonescimab (an immunotherapy drug)
What this could lead to: If successful, this combination could offer a new treatment option for people with hormone receptor-positive, HER2-negative advanced breast cancer, including those with brain metastases.
What could go wrong: This is a small, early-phase study with only 53 participants and no comparison group, so results may not apply broadly. The combination may cause significant side effects, and it is not yet known if it works better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.